Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma

Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma

Abstract Background Even in the era of novel immunotherapies for multiple myeloma (MM), treatment of late‐stage relapsed/refractory (RR) patients remains challenging. The aim of our study was to analyze the efficacy and safety of the five‐drug combination pomalidomide, bortezomib, doxorubicin, dexam...

Full description

Bibliographic Details
Main Authors: Xiang Zhou, Maximilian J. Steinhardt, Denise Grathwohl, Katharina Meckel, Katharina Nickel, Hans‐Benno Leicht, Franziska Krummenast, Hermann Einsele, Leo Rasche, Klaus M. Kortüm
Format: Article
Language:English
Published: Wiley 2020-08-01
Series:Cancer Medicine
Subjects:
multiple myeloma
Pom‐PAD‐Dara
refractory
relapse
Online Access:https://doi.org/10.1002/cam4.3209

Internet

https://doi.org/10.1002/cam4.3209

Similar Items